Open-Label Study of Long-Term Evaluation Against LDL Cholesterol | Clinical Trial - OSLER


The goal of the trial was to assess the longer-term safety and efficacy of evolocumab, a PCSK9 inhibitor, in addition to standard therapy, compared with standard therapy alone.

Contribution to the Literature: The OSLER study suggests that evolocumab in addition to standard medical therapy results in greater LDL-C reduction and a reduction in 1-year composite cardiovascular outcomes compared with standard medical therapy alone.